Osteoporosis Treatment Alternatives to Prolia

Introduction to Alternatives

The American College of Physicians recommends bisphosphonates, specifically alendronate, risedronate, or zoledronic acid, as the preferred first-line alternatives to Prolia for treating osteoporosis, due to their effectiveness in reducing hip, vertebral, and nonvertebral fractures, with the added benefit of residual bone protection for years after discontinuation 1, 2, 3

Alendronate reduces vertebral, nonvertebral, and hip fractures in postmenopausal women with high-quality evidence 1, 4
Risedronate demonstrates similar fracture reduction across all sites 1, 4
Zoledronic acid reduces vertebral fractures by 67% and provides convenient once-yearly dosing, particularly useful for patients with compliance concerns or gastrointestinal intolerance 4, 5
Ibandronate reduces vertebral fractures, though evidence for hip fracture reduction is insufficient 4

Teriparatide reduces vertebral and nonvertebral fractures, and is conditionally recommended over antiresorptive agents in very high-risk patients 8, 4
Romosozumab is limited to 12 monthly doses and should be avoided in patients with high cardiovascular risk due to FDA safety warnings 2

Raloxifene increases the risk of venous thromboembolism, pulmonary embolism, and fatal stroke, and is strongly recommended against 1, 3
Menopausal estrogen therapy has an unfavorable benefit-harm profile and is strongly recommended against 1, 3
Calcium or vitamin D alone has an uncertain effect on fracture risk and is insufficient as monotherapy 4

Treatment with bisphosphonates should initially last for 5 years, then reassess fracture risk to determine if continuation is needed 1, 3
Bone density should not be routinely monitored during the initial 5-year treatment period, as fracture reduction occurs even without BMD increases 1, 3, 7
Ensure adequate supplementation with 1,000-1,200 mg calcium and 600-800 IU vitamin D daily throughout treatment 6